Skip to main content
OpenTrials
Completed

NCT Number: NCT01078909

Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation

The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several inflammatory markers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Penn State University

University Park, Pennsylvania, 16802, United States

About this study

Inflammation is an important biological process initiated by the immune system in response to injury, irritation or infection. Prolonged or chronic inflammation is involved in the etiology of several diseases such as cardiovascular disease (CVD), diabetes, rheumatoid arthritis, cancer, and neurodegenerative diseases such as Alzheimer disease. The evidence base clearly demonstrates benefits of diet in ameliorating inflammation and reducing the burden of chronic disease. With respect to marine-derived omega-3 fatty acids and various markers of inflammation related to cardiovascular disease (CVD), both population studies and randomized controlled supplementation trials have yielded mixed results.

Some studies have demonstrated a dose-response relationship between dietary eicosapentaenoic acid and docosahexaenoic acid (EPA + DHA) and increased membrane (phospholipid) EPA and DHA. Red blood cell (RBC) EPA + DHA content has been proposed as a potential, modifiable marker for coronary heart disease (CHD) risk. It is well established that these fatty acids are precursors of series-3 prostanoids, thromboxanes, 5-series leukotrienes, and novel lipid mediators such as resolvins and protectins that have anti-inflammatory effects. We hypothesize that nutritionally-relevant intakes of omega-3 fatty acids are able to blunt the usual response to an inflammatory stimulus. We propose to test this hypothesis using both in vivo (i.v. endotoxin challenge) and ex vivo (endotoxin-stimulated monocytes) models in a 6-month, dose-response study with marine-derived omega-3 fatty acid supplements in healthy volunteers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy men and non-pregnant/lactating women between the ages of 20 and 45
  • BMI >19.9 and <30.0
  • Able to give written informed consent and willing to comply with all study- related procedures.

Exclusion criteria

  • Previous history of heart disease or diabetes
  • Renal Insufficiency
  • Chronic anti-inflammatory use
  • Systolic blood pressure < 90
  • Individuals currently using tobacco products or have done so in the previous 30 days
  • Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month.

Treatment and study plan

Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)

Biological

Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period

Other names: Omega-3 Fatty Acids, Fish Oil

Primary outcomes

  1. Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment

    Time frame: 5 months

  2. Mean Concentrations of CRP Following 5 Months of Treatment

    Time frame: 5 months

Secondary outcomes

  1. Change in Lipid Mediators

    Time frame: 1, 2, 3 and 5 days post LPS administration

    0 Participants Analyzed; Lipid mediators were unable to be detected therefore there are no data to report.

Sponsors and collaborators

Lead sponsor

Penn State University

Other

Collaborators

  • United States Department of Agriculture (USDA)

Registry information

Important dates

Study start
2011
Primary completion
2012
Study completion
2014
First posted
Mar 2, 2010
Registry last updated
Aug 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.